Alpha-1 Antitrypsin Deficiency Market and Epidemiology Forecast to 2032 [Yahoo! Finance]
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma [Yahoo! Finance]
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target lowered by analysts at Morgan Stanley from $36.00 to $27.00. They now have an "equal weight" rating on the stock.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.